ID   WILL-2
AC   CVCL_1901
SY   WILL2
DR   BioSample; SAMN03473465
DR   DSMZ; ACC-652
DR   DSMZCellDive; ACC-652
DR   GEO; GSM1374990
DR   Wikidata; Q54994083
RX   PubMed=19330555;
RX   PubMed=26727417;
CC   Population: Japanese.
CC   Doubling time: ~36-48 hours (DSMZ=ACC-652).
CC   Omics: Transcriptomics; Microarray.
CC   Derived from site: In situ; Ascites; UBERON=UBERON_0007795.
ST   Source(s): DSMZ=ACC-652
ST   Amelogenin: X
ST   CSF1PO: 10,11
ST   D13S317: 8,9
ST   D16S539: 9,13
ST   D18S51: 13,16
ST   D19S433: 14,17
ST   D21S11: 29,30
ST   D2S1338: 23,24
ST   D3S1358: 15,18
ST   D5S818: 9,12
ST   D7S820: 10,11
ST   D8S1179: 12,13
ST   FGA: 19,21
ST   Penta D: 11
ST   Penta E: 5,14
ST   TH01: 6
ST   TPOX: 11
ST   vWA: 17,18
DI   NCIt; C8851; Diffuse large B-cell lymphoma
DI   ORDO; Orphanet_544; Diffuse large B-cell lymphoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   63Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 10-04-25; Version: 20
//
RX   PubMed=19330555; DOI=10.1007/s12185-009-0295-4;
RA   Sonoki T., Li Y.-Q., Miyanishi S., Nakamine H., Hanaoka N., Matsuoka H.,
RA   Mori I., Nakakuma H.;
RT   "Establishment of a novel CD20 negative mature B-cell line, WILL2,
RT   from a CD20 positive diffuse large B-cell lymphoma patient treated
RT   with rituximab.";
RL   Int. J. Hematol. 89:400-402(2009).
//
RX   PubMed=26727417; DOI=10.3109/10428194.2015.1108414;
RA   Drexler H.G., Eberth S., Nagel S., MacLeod R.A.F.;
RT   "Malignant hematopoietic cell lines: in vitro models for double-hit
RT   B-cell lymphomas.";
RL   Leuk. Lymphoma 57:1015-1020(2016).
//